| Title |
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, May 2018
|
| DOI | 10.1186/s40425-018-0345-7 |
| Pubmed ID | |
| Authors |
Michael Lattanzi, Joseph Han, Una Moran, Kierstin Utter, Jeremy Tchack, Rachel Lubong Sabado, Russell Berman, Richard Shapiro, Hsin-Hui Huang, Iman Osman, Nina Bhardwaj, Anna C. Pavlick |
| Abstract |
Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls. All melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort. All such patients with stage III melanoma were subsequently compared to historical control patients identified via a prospective institutional database with protocol-driven follow-up. Survival times were calculated using the Kaplan-Meier method, and Cox proportional hazard models were employed to identify significant prognostic factors and control for confounding variables. A total of 91 patients were treated with an NY-ESO-1 vaccine for the treatment of high-risk resected melanoma. Of this group, 67 patients were stage III and were selected for comparative analysis with 123 historical control patients with resected stage III melanoma who received no adjuvant therapy. Among the pooled vaccine cohort (median follow-up 61 months), the estimated median recurrence-free survival was 45 months, while the median overall survival was not yet reached. In the control cohort of 123 patients (median follow-up 30 months), the estimated median recurrence-free and overall survival were 22 and 58 months, respectively. Within the retrospective stage III cohort, NY-ESO-1 vaccine was associated with decreased risk of recurrence (HR = 0.56, p < 0.01) and death (HR = 0.51, p = 0.01). Upon controlling for sub-stage, the adjuvant NY-ESO-1 clinical trial cohort continued to exhibit decreased risk of recurrence (HR = 0.45, p < 0.01) and death (HR = 0.40, p < 0.01). In this small retrospective cohort of resected stage III melanoma patients, adjuvant NY-ESO-1 vaccine immunotherapy was associated with longer recurrence-free and overall survival relative to historical controls. These data support the continued investigation of adjuvant NY-ESO-1 based immunotherapy regimens in melanoma. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 60% |
| Spain | 2 | 20% |
| United Kingdom | 1 | 10% |
| Unknown | 1 | 10% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 70% |
| Practitioners (doctors, other healthcare professionals) | 2 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 33 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 12% |
| Student > Doctoral Student | 3 | 9% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Bachelor | 3 | 9% |
| Student > Master | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 16 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 15% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Agricultural and Biological Sciences | 2 | 6% |
| Nursing and Health Professions | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 18 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2022.
All research outputs
#6,498,682
of 25,382,440 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,553
of 3,422 outputs
Outputs of similar age
#104,626
of 343,554 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#30
of 41 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 3,422 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,554 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.